Chemical Component Summary | |
|---|---|
| Name | CARBOXYMETHYLATED CYSTEINE |
| Identifiers | (2R)-2-amino-3-(carboxymethylsulfanyl)propanoic acid |
| Formula | C5 H9 N O4 S |
| Molecular Weight | 179.19 |
| Type | L-PEPTIDE LINKING |
| Isomeric SMILES | N[C@@H](CSCC(O)=O)C(O)=O |
| InChI | InChI=1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1 |
| InChIKey | GBFLZEXEOZUWRN-VKHMYHEASA-N |
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 20 |
| Chiral Atom Count | 1 |
| Chiral Atoms | CA |
| Bond Count | 19 |
| Aromatic Bond Count | 0 |
| Leaving Atoms | OXT, H2, HXT |
Drug Info: DrugBank
| DrugBank ID | DB04339 Different stereochemistry |
|---|---|
| Name | Carbocisteine |
| Groups | approved |
| Description | Carbocisteine is a mucolytic that reduces the viscosity of sputum and so can be used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing the sufferer to bring up sputum more easily. Carbocisteine should not be used with antitussives (cough suppressants) or medicines that dry up bronchial secretions. Carbocisteine is produced by alkylation of cysteine with chloroacetic acid. |
| Synonyms | S-carboxymethylcysteine |
| Brand Names |
|
| Affected Organism | Humans and other mammals |
| Indication | Used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis. |
| Categories |
|
| ATC-Code | R05CB03 |
| CAS number | 638-23-3 |
Drug Targets
| Name | Sequence Search | Pharmacological Action | Actions |
|---|---|---|---|
| Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLY... | unknown |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
